ArticleNucleic acids research2025
The flap endonuclease-1 promotes cellular tolerance to a chain-terminating nucleoside analog, alovudine, by counteracting the toxic effect of 53BP1.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Genome Maintenance Defects of Cancers Using Chain-Terminating Nucleoside Analogs.Cancer science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chain-terminating nucleoside analogs (CTNAs) are frequently used as antiviral and anticancer agents. CTNAs are incorporated into the end of nascent DNA during DNA synthesis and inhibit subsequent DNA polymerization, thereby restricting the proliferation of viruses and cancer cells. Alovudine, a thymidine analog, exerts chain-termination effects and is used as an antiviral drug. However, the mechanisms underlying cellular tolerance to alovudine have not been fully elucidated. Here, we show that flap endonuclease-1 (Fen1) and p53 binding protein-1 (53BP1) counteractively mitigate the chain-terminating effect of alovudine. We found that the cells deficient in Fen1 (FEN1-/-) showed stronger chain-terminating effects of alovudine with augmented DNA damage than wild-type cells, leading to their alovudine hypersensitivity. Moreover, we found that the Okazaki fragment maturation was critically slowed in FEN1-/- cells when cells were challenged with alovudine. Remarkably, the loss of 53BP1 rescued these phenotypes. We found that 53BP1 formed sub-nuclear foci upon alovudine treatment and these 53BP1 foci were critically increased in FEN1-/- cells, indicating that Fen1 suppresses alovudine-mediated toxic 53BP1 subnuclear foci thereby promoting Okazaki fragment maturation and suppressing DNA damage. In this study, we uncovered the previously unappreciated role of Fen1 in the suppression of toxic action of 53BP1 at alovudine-incorporated Okazaki fragment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.